|
19 Sep 2023 |
Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue™ Discovery Platform
|
|
19 Sep 2023 |
ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma
|
|
19 Sep 2023 |
AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases
|
|
19 Sep 2023 |
MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
|
|
19 Sep 2023 |
Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003
|
|
19 Sep 2023 |
Pharmanovia acquires global central nervous system (CNS) portfolio from Sanofi
|
|
19 Sep 2023 |
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
|
|
19 Sep 2023 |
LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
|
|
19 Sep 2023 |
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
|
|
19 Sep 2023 |
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
|
|
19 Sep 2023 |
ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program
|
|
19 Sep 2023 |
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
|
|
19 Sep 2023 |
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
|
|
19 Sep 2023 |
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
19 Sep 2023 |
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
|
|
19 Sep 2023 |
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
|
|
19 Sep 2023 |
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
|
|
18 Sep 2023 |
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
|
|
18 Sep 2023 |
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
|
|
18 Sep 2023 |
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
|
